Close to a record number of attendees tonight – 27 is the largest since we went to weekly groups! Thanks everyone ….. rd
Editor’s Pick – the Covid19 virus may force you to delay appointments for repeat treatments – we discuss half-lives of drugs you are taking.
Topics discussed
monitoring post-salvage treatment; IHT for high volume PCa; using a GU med onc; addressing erectile dysfunction; radiation at Mayo, Phoenix; failure to prescribe buffer starting ADT; half life of LHRH and bone strengtheners; salvage cryotherapy to pre-treated spot lesion; NGS tumor sequencing in Canada
Editor’s Pick – it ain’t over til the Fat Lady sings, so wait until the very end to hear us uncover a rarely used form of ADT that been around since 2006 and is given annually.
Please note that changes made by both GoToMeeting and YouTube make the transcript unavailable this week. We are investigating if we can resolve.
Viewing our videos; testosterone spikes after recurrent shot – but is this an error?; coronavirus precautions; spot radiation experience; TP53 mutation; is it worth treating the primary with metastatic disease; coordinating local and quarterback doctors; MPCP; starting hormone therapy; Eligard vs Lupron; Vantas – a 12-month LHRH pellet
Editor’s choice: Learn first hand about certain side effects from the immunotherapy drug, nivolumab (Opdivo).
Pharmokinetics of Lupron – explained a little; side effects of immunotherapy anti-PD1 drug Opdivo; treating liver metastasis; getting palliative doc involved; durolutamide results; starting ADT froom scratch; monitoring G5+5 PCa after you come off LHRH; what to know when starting chemo; neuropathy and maybe how to prevent it from chemo
Chat Log
Russ Smith (to Everyone): 7:20 PM: Turns out I was given a script today for Casodex.
Ken Anderson (to Everyone): 7:22 PM: Russ
Ken Anderson (to Everyone): 7:22 PM: good to know!
Editor’s Pick – ATM and TP53 mutations may increase risk of radiation damage.
Treatment after 2nd line anti-androgen fails; CARD trial & Jevtana/cabazitaxel; finding a trial close to home; is chemo best early or late?; somatic mutations can change; osteopenia – what to do; ADT driven anemia; ATM & TP53 mutations may increase risk for radiation damage; dealing with pain before and after cancer Dx
Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated DGrade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
At the time, prostate cancer advocates objected strongly, warning it would result in many more men diagnosed de novo metastatic, and ultimately more disease specific deaths.
Sadly, we have seen this manifested, especially with respect to younger men. AnCan clearly sees the trend along with a lack of support for the particular needs expressed by younger men living with advanced prostate cancer. Along with our partner, UsTOO, we have established an Under-60 Advanced Prostate Cancer Virtual Group to address these needs.
——————————————————————————————————–
2nd Thursday of each month at 7 pm Eastern in The Barniskis Room (222-583-973)
